Class i HDACs Affect DNA Replication, Repair, and Chromatin Structure: Implications for Cancer Therapy

Antioxidants and Redox Signaling

Volumn 23, Issue 1, 2015, Pages 51-65

  Stengel, Kristy R ^a   Hiebert, Scott W ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR I; UNCLASSIFIED DRUG; CHROMATIN; DEPSIPEPTIDE; HISTONE DEACETYLASE; HYDROXAMIC ACID; ROMIDEPSIN; VORINOSTAT;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; CANCER THERAPY; CARCINOGENESIS; CELL KILLING; CHROMATIN STRUCTURE; DNA REPAIR; DNA REPLICATION; DRUG EFFECT; DRUG EFFICACY; GENE EXPRESSION; GENOMIC INSTABILITY; HETEROCHROMATIN; HISTONE ACETYLATION; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; TOXICITY TESTING; ACETYLATION; ANIMAL; CHEMISTRY; CHROMATIN; DRUG EFFECTS; HUMAN; METABOLISM; NEOPLASMS;

ACETYLATION; ANIMALS; CHROMATIN; DEPSIPEPTIDES; DNA REPAIR; DNA REPLICATION; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; NEOPLASMS;

EID: 84934891907     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2014.5915     Document Type: Review

References (137)

1. Adimoolam S, Sirisawad M, Chen J, Thiemann P, Ford JM, and Buggy JJ. HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc Natl Acad Sci U S A 104: 19482-19487, 2007.
2. Aggarwal BD and Calvi BR. Chromatin regulates origin activity in Drosophila follicle cells. Nature 430: 372-376, 2004.
3. Ahmad A, Takami Y, and Nakayama T. WD repeats of the p48 subunit of chicken chromatin assembly factor-1 required for in vitro interaction with chicken histone deacetylase-2. J Biol Chem 274: 16646-16653, 1999.
4. Alabert C and Groth A. Chromatin replication and epigenome maintenance. Nat Rev Mol Cell Biol 13: 153-167, 2012.
5. Alenghat T, Meyers K, Mullican SE, Leitner K, Adeniji-Adele A, Avila J, Bucan M, Ahima RS, Kaestner KH, and Lazar MA. Nuclear receptor corepressor and histone deacetylase 3 govern circadian metabolic physiology. Nature 456: 997-1000, 2008.
6. Aliouat-Denis CM, Dendouga N, Van den Wyngaert I, Goehlmann H, Steller U, van de Weyer I, Van Slycken N, Andries L, Kass S, Luyten W, Janicot M, and Vialard JE. p53-independent regulation of p21Waf1/Cip1 expression and senescence by Chk2. Mol Cancer Res 3: 627-634, 2005.
7. Amann JM, Nip J, Strom DK, Lutterbach B, Harada H, Lenny N, Downing JR, Meyers S, and Hiebert SW. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol Cell Biol 21: 6470-6483, 2001.
8. Aparicio JG, Viggiani CJ, Gibson DG, and Aparicio OM. The Rpd3-Sin3 histone deacetylase regulates replication timing and enables intra-S origin control in Saccharomyces cerevisiae. Mol Cell Biol 24: 4769-4780, 2004.
9. Balasubramanian S, Verner E, and Buggy JJ. Isoform-specific histone deacetylase inhibitors: the next step? Cancer Lett 280: 211-221, 2009.
10. Bereshchenko OR, Gu W, and Dalla-Favera R. Acetylation inactivates the transcriptional repressor BCL6. Nat Genet 32: 606-613, 2002.
11. Bhaskara S, Chyla BJ, Amann JM, Knutson SK, Cortez D, Sun ZW, and Hiebert SW. Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Mol Cell 30: 61-72, 2008.
12. Bhaskara S, Jacques V, Rusche JR, Olson EN, Cairns BR, and Chandrasekharan MB. Histone deacetylases 1 and 2 maintain S-phase chromatin and DNA replication fork progression. Epigenetics Chromatin 6: 27, 2013.
13. Bhaskara S, Knutson SK, Jiang G, Chandrasekharan MB, Wilson AJ, Zheng S, Yenamandra A, Locke K, Yuan JL, Bonine-Summers AR, Wells CE, Kaiser JF, Washington MK, Zhao Z, Wagner FF, Sun ZW, Xia F, Holson EB, Khabele D, and Hiebert SW. Hdac3 is essential for the maintenance of chromatin structure and genome stability. Cancer Cell 18: 436-447, 2010.
14. Bishton MJ, Harrison SJ, Martin BP, McLaughlin N, James C, Josefsson EC, Henley KJ, Kile BT, Prince HM, and Johnstone RW. Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia. Blood 117: 3658-3668, 2011.
15. Bruserud O, Stapnes C, Tronstad KJ, Ryningen A, Anensen N, and Gjertsen BT. Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML. Expert Opin Ther Targets 10: 51-68, 2006.
16. Burgess AJ, Pavey S, Warrener R, Hunter LJ, Piva TJ, Musgrove EA, Saunders N, Parsons PG, and Gabrielli BG. Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity. Mol Pharmacol 60: 828-837, 2001.
17. Burhans WC and Weinberger M. DNA replication stress, genome instability and aging. Nucleic Acids Res 35: 7545-7556, 2007.
18. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, and Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2: 401-404, 2012.
19. Cerchietti LC, Ghetu AF, Zhu X, Da Silva GF, Zhong S, Matthews M, Bunting KL, Polo JM, Fares C, Arrowsmith CH, Yang SN, Garcia M, Coop A, Mackerell Jr., AD, Prive GG, and Melnick A. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell 17: 400-411, 2010.
20. Chen X, Barozzi I, Termanini A, Prosperini E, Recchiuti A, Dalli J, Mietton F, Matteoli G, Hiebert S, and Natoli G. Requirement for the histone deacetylase Hdac3 for the inflammatory gene expression program in macrophages. Proc Natl Acad Sci U S A 109: E2865-E2874, 2012.
21. Chen Y, Wang H, Yoon SO, Xu X, Hottiger MO, Svaren J, Nave KA, Kim HA, Olson EN, and Lu QR. HDAC-mediated deacetylation of NF-kappaB is critical for Schwann cell myelination. Nat Neurosci 14: 437-441, 2011.
22. Chi P, Allis CD, and Wang GG. Covalent histone modifications - miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer 10: 457-469, 2010.
23. Choi YH and Yoo YH. Taxol-induced growth arrest and apoptosis is associated with the upregulation of the Cdk inhibitor, p21WAF1/CIP1, in human breast cancer cells. Oncol Rep 28: 2163-2169, 2012.
24. Clemente-Ruiz M and Prado F. Chromatin assembly controls replication fork stability. EMBO Rep 10: 790-796, 2009.
25. Conti C, Leo E, Eichler GS, Sordet O, Martin MM, Fan A, Aladjem MI, and Pommier Y. Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage. Cancer Res 70: 4470-4480, 2010.
26. Courbet S, Gay S, Arnoult N, Wronka G, Anglana M, Brison O, and Debatisse M. Replication fork movement sets chromatin loop size and origin choice in mammalian cells. Nature 455: 557-560, 2008.
27. Das C, Lucia MS, Hansen KC, and Tyler JK. CBP/p300-mediated acetylation of histone H3 on lysine 56. Nature 459: 113-117, 2009.
28. Davoli T, Xu AW, Mengwasser KE, Sack LM, Yoon JC, Park PJ, and Elledge SJ. Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome. Cell 155: 948-962, 2013.
29. Dawson MA and Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 150: 12-27, 2012.
30. Dobbin MM, Madabhushi R, Pan L, Chen Y, Kim D, Gao J, Ahanonu B, Pao PC, Qiu Y, Zhao Y, and Tsai LH. SIRT1 collaborates with ATM and HDAC1 to maintain genomic stability in neurons. Nat Neurosci 16: 1008-1015, 2013.
31. Ekwall K, Olsson T, Turner BM, Cranston G, and Allshire RC. Transient inhibition of histone deacetylation alters the structural and functional imprint at fission yeast centromeres. Cell 91: 1021-1032, 1997.
32. Filippakopoulos P and Knapp S. The bromodomain interaction module. FEBS Lett 586: 2692-2704, 2012.
33. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, and Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6: pl1, 2013.
34. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, and Davidsen SK. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2: 151-163, 2003.
35. Gong F and Miller KM. Mammalian DNA repair: HATs and HDACs make their mark through histone acetylation. Mutat Res 750: 23-30, 2013.
36. Grausenburger R, Bilic I, Boucheron N, Zupkovitz G, El-Housseiny L, Tschismarov R, Zhang Y, Rembold M, Gaisberger M, Hartl A, Epstein MM, Matthias P, Seiser C, and Ellmeier W. Conditional deletion of histone deacetylase 1 in T cells leads to enhanced airway inflammation and increased Th2 cytokine production. J Immunol 185: 3489-3497, 2010.
37. Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, Fanelli M, Ruthardt M, Ferrara FF, Zamir I, Seiser C, Lazar MA, Minucci S, and Pelicci PG. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 391: 815-818, 1998.
38. Groth A, Rocha W, Verreault A, and Almouzni G. Chromatin challenges during DNA replication and repair. Cell 128: 721-733, 2007.
39. Guan JS, Haggarty SJ, Giacometti E, Dannenberg JH, Joseph N, Gao J, Nieland TJ, Zhou Y, Wang X, Mazitschek R, Bradner JE, DePinho RA, Jaenisch R, and Tsai LH. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 459: 55-60, 2009.
40. Gui CY, Ngo L, Xu WS, Richon VM, and Marks PA. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci U S A 101: 1241-1246, 2004.
41. Guillou E, Ibarra A, Coulon V, Casado-Vela J, Rico D, Casal I, Schwob E, Losada A, and Mendez J. Cohesin organizes chromatin loops at DNA replication factories. Genes Dev 24: 2812-2822, 2010.
42. Haberland M, Johnson A, Mokalled MH, Montgomery RL, and Olson EN. Genetic dissection of histone deacetylase requirement in tumor cells. Proc Natl Acad Sci U S A 106: 7751-7755, 2009.
43. Harikrishnan KN, Karagiannis TC, Chow MZ, and El-Osta A. Effect of valproic acid on radiation-induced DNA damage in euchromatic and heterochromatic compartments. Cell Cycle 7: 468-476, 2008.
44. He LZ, Tolentino T, Grayson P, Zhong S, Warrell Jr., RP, Rifkind RA, Marks PA, Richon VM, and Pandolfi PP. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest 108: 1321-1330, 2001.
45. Heideman MR, Wilting RH, Yanover E, Velds A, de Jong J, Kerkhoven RM, Jacobs H, Wessels LF, and Dannenberg JH. Dosage-dependent tumor suppression by histone deacetylases 1 and 2 through regulation of c-Myc collaborating genes and p53 function. Blood 121: 2038-2050, 2013.
46. Helbling Chadwick L, Chadwick BP, Jaye DL, and Wade PA. The Mi-2/NuRD complex associates with pericentromeric heterochromatin during S phase in rapidly proliferating lymphoid cells. Chromosoma 118: 445-457, 2009.
47. Hsiao KY and Mizzen CA. Histone H4 deacetylation facilitates 53BP1 DNA damage signaling and double-strand break repair. J Mol Cell Biol 5: 157-165, 2013.
48. Huang L and Pardee AB. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol Med 6: 849-866, 2000.
49. Huang L, Sowa Y, Sakai T, and Pardee AB. Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene 19: 5712-5719, 2000.
50. Huynh KD and Bardwell VJ. The BCL-6 POZ domain and other POZ domains interact with the co-repressors N-CoR and SMRT. Oncogene 17: 2473-2484, 1998.
51. Huynh KD, Fischle W, Verdin E, and Bardwell VJ. BCoR, a novel corepressor involved in BCL-6 repression. Genes Dev 14: 1810-1823, 2000.
52. Jacob C, Christen CN, Pereira JA, Somandin C, Baggiolini A, Lotscher P, Ozcelik M, Tricaud N, Meijer D, Yamaguchi T, Matthias P, and Suter U. HDAC1 and HDAC2 control the transcriptional program of myelination and the survival of Schwann cells. Nat Neurosci 14: 429-436, 2011.
53. Jawerka M, Colak D, Dimou L, Spiller C, Lagger S, Montgomery RL, Olson EN, Wurst W, Gottlicher M, and Gotz M. The specific role of histone deacetylase 2 in adult neurogenesis. Neuron Glia Biol 6: 93-107, 2010.
54. Johnstone RW and Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4: 13-18, 2003.
55. Ju R and Muller MT. Histone deacetylase inhibitors activate p21(WAF1) expression via ATM. Cancer Res 63: 2891-2897, 2003.
56. Juan LJ, Shia WJ, Chen MH, Yang WM, Seto E, Lin YS, and Wu CW. Histone deacetylases specifically downregulate p53-dependent gene activation. J Biol Chem 275: 20436-20443, 2000.
57. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, Leiserson MD, Miller CA, Welch JS, Walter MJ, Wendl MC, Ley TJ, Wilson RK, Raphael BJ, and Ding L. Mutational landscape and significance across 12 major cancer types. Nature 502: 333-339, 2013.
58. Karagiannis TC and El-Osta A. Chromatin modifications and DNA double-strand breaks: the current state of play. Leukemia 21: 195-200, 2007.
59. Karagiannis TC and El-Osta A. Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds? Leukemia 21: 61-65, 2007.
60. Kim GD, Choi YH, Dimtchev A, Jeong SJ, Dritschilo A, and Jung M. Sensing of ionizing radiation-induced DNA damage by ATM through interaction with histone deacetylase. J Biol Chem 274: 31127-31130, 1999.
61. Knott SR, Viggiani CJ, Tavare S, and Aparicio OM. Genome-wide replication profiles indicate an expansive role for Rpd3L in regulating replication initiation timing or efficiency, and reveal genomic loci of Rpd3 function in Saccharomyces cerevisiae. Genes Dev 23: 1077-1090, 2009.
62. Knutson SK, Chyla BJ, Amann JM, Bhaskara S, Huppert SS, and Hiebert SW. Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks. EMBO J 27: 1017-1028, 2008.
63. Lagger G, O'Carroll D, Rembold M, Khier H, Tischler J, Weitzer G, Schuettengruber B, Hauser C, Brunmeir R, Jenuwein T, and Seiser C. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 21: 2672-2681, 2002.
64. LeBoeuf M, Terrell A, Trivedi S, Sinha S, Epstein JA, Olson EN, Morrisey EE, and Millar SE. Hdac1 and Hdac2 act redundantly to control p63 and p53 functions in epidermal progenitor cells. Dev Cell 19: 807-818, 2010.
65. Lee JH, Choy ML, Ngo L, Foster SS, and Marks PA. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc Natl Acad Sci U S A 107: 14639-14644, 2010.
66. Leoni F, Zaliani A, Bertolini G, Porro G, Pagani P, Pozzi P, Dona G, Fossati G, Sozzani S, Azam T, Bufler P, Fantuzzi G, Goncharov I, Kim SH, Pomerantz BJ, Reznikov LL, Siegmund B, Dinarello CA, and Mascagni P. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci U S A 99: 2995-3000, 2002.
67. Li Y, Kao GD, Garcia BA, Shabanowitz J, Hunt DF, Qin J, Phelan C, and Lazar MA. A novel histone deacetylase pathway regulates mitosis by modulating Aurora B kinase activity. Genes Dev 20: 2566-2579, 2006.
68. Lindemann RK, Gabrielli B, and Johnstone RW. Histone-deacetylase inhibitors for the treatment of cancer. Cell Cycle 3: 779-788, 2004.
69. Luger K, Rechsteiner TJ, Flaus AJ, Waye MM, and Richmond TJ. Characterization of nucleosome core particles containing histone proteins made in bacteria. J Mol Biol 272: 301-311, 1997.
70. Luo RX, Postigo AA, and Dean DC. Rb interacts with histone deacetylase to repress transcription. Cell 92: 463-473, 1998.
71. Ma P, Pan H, Montgomery RL, Olson EN, and Schultz RM. Compensatory functions of histone deacetylase 1 (HDAC1) and HDAC2 regulate transcription and apoptosis during mouse oocyte development. Proc Natl Acad Sci U S A 109: E481-E489, 2012.
72. Ma P and Schultz RM. Histone deacetylase 2 (HDAC2) regulates chromosome segregation and kinetochore function via H4K16 deacetylation during oocyte maturation in mouse. PLoS Genet 9: e1003377, 2013.
73. Magnaghi-Jaulin L, Groisman R, Naguibneva I, Robin P, Lorain S, Le Villain JP, Troalen F, Trouche D, and Harel-Bellan A. Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature 391: 601-605, 1998.
74. Mechali M. Eukaryotic DNA replication origins: many choices for appropriate answers. Nat Rev Mol Cell Biol 11: 728-738, 2010.
75. Millard CJ, Watson PJ, Celardo I, Gordiyenko Y, Cowley SM, Robinson CV, Fairall L, and Schwabe JW. Class I HDACs share a common mechanism of regulation by inositol phosphates. Mol Cell 51: 57-67, 2013.
76. Miller KM, Tjeertes JV, Coates J, Legube G, Polo SE, Britton S, and Jackson SP. Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining. Nat Struct Mol Biol 17: 1144-1151, 2010.
77. Milutinovic S, Zhuang Q, and Szyf M. Proliferating cell nuclear antigen associates with histone deacetylase activity, integrating DNA replication and chromatin modification. J Biol Chem 277: 20974-20978, 2002.
78. Miotto B and Struhl K. HBO1 histone acetylase activity is essential for DNA replication licensing and inhibited by Geminin. Mol Cell 37: 57-66, 2010.
79. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, Akiyama M, Chauhan D, Munshi N, Gu X, Bailey C, Joseph M, Libermann TA, Richon VM, Marks PA, and Anderson KC. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A 101: 540-545, 2004.
80. Montgomery RL, Davis CA, Potthoff MJ, Haberland M, Fielitz J, Qi X, Hill JA, Richardson JA, and Olson EN. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev 21: 1790-1802, 2007.
81. Montgomery RL, Hsieh J, Barbosa AC, Richardson JA, and Olson EN. Histone deacetylases 1 and 2 control the progression of neural precursors to neurons during brain development. Proc Natl Acad Sci U S A 106: 7876-7881, 2009.
82. Montgomery RL, Potthoff MJ, Haberland M, Qi X, Matsuzaki S, Humphries KM, Richardson JA, Bassel-Duby R, and Olson EN. Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice. J Clin Invest 118: 3588-3597, 2008.
83. Mullican SE, Gaddis CA, Alenghat T, Nair MG, Giacomin PR, Everett LJ, Feng D, Steger DJ, Schug J, Artis D, and Lazar MA. Histone deacetylase 3 is an epigenomic brake in macrophage alternative activation. Genes Dev 25: 2480-2488, 2011.
84. Murphy M, Ahn J, Walker KK, Hoffman WH, Evans RM, Levine AJ, and George DL. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev 13: 2490-2501, 1999.
85. Nakano K, Mizuno T, Sowa Y, Orita T, Yoshino T, Okuyama Y, Fujita T, Ohtani-Fujita N, Matsukawa Y, Tokino T, Yamagishi H, Oka T, Nomura H, and Sakai T. Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. J Biol Chem 272: 22199-22206, 1997.
86. Naryzhny SN and Lee H. The post-translational modifications of proliferating cell nuclear antigen: acetylation, not phosphorylation, plays an important role in the regulation of its function. J Biol Chem 279: 20194-20199, 2004.
87. Nicolas E, Ait-Si-Ali S, and Trouche D. The histone deacetylase HDAC3 targets RbAp48 to the retinoblastoma protein. Nucleic Acids Res 29: 3131-3136, 2001.
88. Odenike OM, Alkan S, Sher D, Godwin JE, Huo D, Brandt SJ, Green M, Xie J, Zhang Y, Vesole DH, Stiff P, Wright J, Larson RA, and Stock W. Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia. Clin Cancer Res 14: 7095-7101, 2008.
89. Pasini D, Malatesta M, Jung HR, Walfridsson J, Willer A, Olsson L, Skotte J, Wutz A, Porse B, Jensen ON, and Helin K. Characterization of an antagonistic switch between histone H3 lysine 27 methylation and acetylation in the transcriptional regulation of Polycomb group target genes. Nucleic Acids Res 38: 4958-4969, 2010.
90. Peart MJ, Smyth GK, van Laar RK, Bowtell DD, Richon VM, Marks PA, Holloway AJ, and Johnstone RW. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci U S A 102: 3697-3702, 2005.
91. Pettazzoni P, Pizzimenti S, Toaldo C, Sotomayor P, Tagliavacca L, Liu S, Wang D, Minelli R, Ellis L, Atadja P, Ciamporcero E, Dianzani MU, Barrera G, and Pili R. Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cells. Free Radic Biol Med 50: 313-322, 2011.
92. Piekarz RL, Frye AR, Wright JJ, Steinberg SM, Liewehr DJ, Rosing DR, Sachdev V, Fojo T, and Bates SE. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res 12: 3762-3773, 2006.
93. Rahmani M, Yu C, Reese E, Ahmed W, Hirsch K, Dent P, and Grant S. Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase inhibitor-mediated apoptosis through p44/42 MAP kinase inactivation and abrogation of p21(CIP1/WAF1) induction rather than AKT inhibition. Oncogene 22: 6231-6242, 2003.
94. Rangwala S, Zhang C, and Duvic M. HDAC inhibitors for the treatment of cutaneous T-cell lymphomas. Future Med Chem 4: 471-486, 2012.
95. Razidlo DF, Whitney TJ, Casper ME, McGee-Lawrence ME, Stensgard BA, Li X, Secreto FJ, Knutson SK, Hiebert SW, and Westendorf JJ. Histone deacetylase 3 depletion in osteo/chondroprogenitor cells decreases bone density and increases marrow fat. PLoS One 5: e11492, 2010.
96. Reichert N, Choukrallah MA, and Matthias P. Multiple roles of class I HDACs in proliferation, differentiation, and development. Cell Mol Life Sci 69: 2173-2187, 2012.
97. Richon VM, Sandhoff TW, Rifkind RA, and Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A 97: 10014-10019, 2000.
98. Robert C and Rassool FV. HDAC inhibitors: roles of DNA damage and repair. Adv Cancer Res 116: 87-129, 2012.
99. Rosato RR, Almenara JA, Maggio SC, Coe S, Atadja P, Dent P, and Grant S. Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions. Mol Cancer Ther 7: 3285-3297, 2008.
100. Rosato RR, Wang Z, Gopalkrishnan RV, Fisher PB, and Grant S. Evidence of a functional role for the cyclindependent kinase-inhibitor p21WAF1/CIP1/MDA6 in promoting differentiation and preventing mitochondrial dysfunction and apoptosis induced by sodium butyrate in human myelomonocytic leukemia cells (U937). Int J Oncol 19: 181-191, 2001.
101. Roy S, Packman K, Jeffrey R, and Tenniswood M. Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells. Cell Death Differ 12: 482-491, 2005.
102. Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R, Smyth MJ, and Johnstone RW. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci U S A 98: 10833-10838, 2001.
103. Russo T, Zambrano N, Esposito F, Ammendola R, Cimino F, Fiscella M, Jackman J, O'Connor PM, Anderson CW, and Appella E. A p53-independent pathway for activation of WAF1/CIP1 expression following oxidative stress. J Biol Chem 270: 29386-29391, 1995.
104. Santoro F, Botrugno OA, Dal Zuffo R, Pallavicini I, Matthews GM, Cluse L, Barozzi I, Senese S, Fornasari L, Moretti S, Altucci L, Pelicci PG, Chiocca S, Johnstone RW, and Minucci S. A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance. Blood 121: 3459-3468, 2013.
105. Shah MH, Binkley P, Chan K, Xiao J, Arbogast D, Collamore M, Farra Y, Young D, and Grever M. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res 12: 3997-4003, 2006.
106. Sims JK and Wade PA. Mi-2/NuRD complex function is required for normal S phase progression and assembly of pericentric heterochromatin. Mol Biol Cell 22: 3094-3102, 2011.
107. Sirbu BM, Couch FB, and Cortez D. Monitoring the spatiotemporal dynamics of proteins at replication forks and in assembled chromatin using isolation of proteins on nascent DNA. Nat Protoc 7: 594-605, 2012.
108. Sirbu BM, Couch FB, Feigerle JT, Bhaskara S, Hiebert SW, and Cortez D. Analysis of protein dynamics at active, stalled, and collapsed replication forks. Genes Dev 25: 1320-1327, 2011.
109. Song J, Lafont A, Chen J, Wu FM, Shirahige K, and Rankin S. Cohesin acetylation promotes sister chromatid cohesion only in association with the replication machinery. J Biol Chem 287: 34325-34336, 2012.
110. Sowa Y, Orita T, Minamikawa S, Nakano K, Mizuno T, Nomura H, and Sakai T. Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem Biophys Res Commun 241: 142-150, 1997.
111. Strait KA, Warnick CT, Ford CD, Dabbas B, Hammond EH, and Ilstrup SJ. Histone deacetylase inhibitors induce G2-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2-related protein Bad. Mol Cancer Ther 4: 603-611, 2005.
112. Summers AR, Fischer MA, Stengel KR, Zhao Y, Kaiser JF, Wells CE, Hunt A, Bhaskara S, Luzwick JW, Sampathi S, Chen X, Thompson M, Cortez D, and Hiebert SW. HDAC3 is essential for DNA replication in hematopoietic progenitor cells. J Clin Invest 123: 3112-3123, 2013.
113. Sun Y, Jiang X, Xu Y, Ayrapetov MK, Moreau LA, Whetstine JR, and Price BD. Histone H3 methylation links DNA damage detection to activation of the tumour suppressor Tip60. Nat Cell Biol 11: 1376-1382, 2009.
114. Sun Z, Feng D, Fang B, Mullican SE, You SH, Lim HW, Everett LJ, Nabel CS, Li Y, Selvakumaran V, Won KJ, and Lazar MA. Deacetylase-independent function of HDAC3 in transcription and metabolism requires nuclear receptor corepressor. Mol Cell 52: 769-782, 2013.
115. Taddei A, Maison C, Roche D, and Almouzni G. Reversible disruption of pericentric heterochromatin and centromere function by inhibiting deacetylases. Nat Cell Biol 3: 114-120, 2001.
116. Taddei A, Roche D, Bickmore WA, and Almouzni G. The effects of histone deacetylase inhibitors on heterochromatin: implications for anticancer therapy? EMBO Rep 6: 520-524, 2005.
117. Tang J, Cho NW, Cui G, Manion EM, Shanbhag NM, Botuyan MV, Mer G, and Greenberg RA. Acetylation limits 53BP1 association with damaged chromatin to promote homologous recombination. Nat Struct Mol Biol 20: 317-325, 2013.
118. Tang J, Yan H, and Zhuang S. Histone deacetylases as targets for treatment of multiple diseases. Clin Sci (Lond) 124: 651-662, 2013.
119. Thapa P, Das J, McWilliams D, Shapiro M, Sundsbak R, Nelson-Holte M, Tangen S, Anderson J, Desiderio S, Hiebert S, Sant'angelo DB, and Shapiro VS. The transcriptional repressor NKAP is required for the development of iNKT cells. Nat Commun 4: 1582, 2013.
120. Thurn KT, Thomas S, Raha P, Qureshi I, and Munster PN. Histone deacetylase regulation of ATM-mediated DNA damage signaling. Mol Cancer Ther 12: 2078-2087, 2013.
121. Tie F, Furuyama T, Prasad-Sinha J, Jane E, and Harte PJ. The Drosophila Polycomb group proteins ESC and E(Z) are present in a complex containing the histone-binding protein p55 and the histone deacetylase RPD3. Development 128: 275-286, 2001.
122. Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G, Ngo L, Holmgren A, Jiang X, and Marks PA. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci U S A 102: 673-678, 2005.
123. Van Lint C, Emiliani S, and Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr 5: 245-253, 1996.
124. Ververis K, Hiong A, Karagiannis TC, and Licciardi PV. Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics 7: 47-60, 2013.
125. Vogelauer M, Rubbi L, Lucas I, Brewer BJ, and Grunstein M. Histone acetylation regulates the time of replication origin firing. Mol Cell 10: 1223-1233, 2002.
126. Warrener R, Chia K, Warren WD, Brooks K, and Gabrielli B. Inhibition of histone deacetylase 3 produces mitotic defects independent of alterations in histone H3 lysine 9 acetylation and methylation. Mol Pharmacol 78: 384-393, 2010.
127. Watson PJ, Fairall L, Santos GM, and Schwabe JW. Structure of HDAC3 bound to co-repressor and inositol tetraphosphate. Nature 481: 335-340, 2012.
128. Wells CE, Bhaskara S, Stengel KR, Zhao Y, Sirbu B, Chagot B, Cortez D, Khabele D, Chazin WJ, Cooper AJ, V., Rusche J, Eischen CM, McGirt LY, and Hiebert SW. Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma. PLoS One 8: e68915, 2013.
129. Wilting RH, Yanover E, Heideman MR, Jacobs H, Horner J, van der Torre J, DePinho RA, and Dannenberg JH. Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis. EMBO J 29: 2586-2597, 2010.
130. Xu WS, Parmigiani RB, and Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26: 5541-5552, 2007.
131. Yamaguchi T, Cubizolles F, Zhang Y, Reichert N, Kohler H, Seiser C, and Matthias P. Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression. Genes Dev 24: 455-469, 2010.
132. Ye F, Chen Y, Hoang T, Montgomery RL, Zhao XH, Bu H, Hu T, Taketo MM, van Es JH, Clevers H, Hsieh J, Bassel-Duby R, Olson EN, and Lu QR. HDAC1 and HDAC2 regulate oligodendrocyte differentiation by disrupting the beta-catenin-TCF interaction. Nat Neurosci 12: 829-838, 2009.
133. Ye X, Franco AA, Santos H, Nelson DM, Kaufman PD, and Adams PD. Defective S phase chromatin assembly causes DNA damage, activation of the S phase checkpoint, and S phase arrest. Mol Cell 11: 341-351, 2003.
134. Zhang C, Richon V, Ni X, Talpur R, and Duvic M. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol 125: 1045-1052, 2005.
135. Ziesche E, Kettner-Buhrow D, Weber A, Wittwer T, Jurida L, Soelch J, Muller H, Newel D, Kronich P, Schneider H, Dittrich-Breiholz O, Bhaskara S, Hiebert SW, Hottiger MO, Li H, Burstein E, Schmitz ML, and Kracht M. The coactivator role of histone deacetylase 3 in IL-1-signaling involves deacetylation of p65 NF-kappaB. Nucleic Acids Res 41: 90-109, 2013.
136. Zullo JM, Demarco IA, Pique-Regi R, Gaffney DJ, Epstein CB, Spooner CJ, Luperchio TR, Bernstein BE, Pritchard JK, Reddy KL, and Singh H. DNA sequence-dependent compartmentalization and silencing of chromatin at the nuclear lamina. Cell 149: 1474-1487, 2012.
137. Zupkovitz G, Grausenburger R, Brunmeir R, Senese S, Tischler J, Jurkin J, Rembold M, Meunier D, Egger G, Lagger S, Chiocca S, Propst F, Weitzer G, and Seiser C. The cyclin-dependent kinase inhibitor p21 is a crucial target for histone deacetylase 1 as a regulator of cellular proliferation. Mol Cell Biol 30: 1171-1181, 2010.